StockMarketWire.com - Diurnal Group has successfully dosed the first patient in a food matrix compatibility study for Infacort in healthy volunteers.

It said this study supported the planned US registration package for Infacort for the treatment of paediatric adrenal insufficiency.

It said that as previously announced, Diurnal would initiate the pivotal phase III clinical trial in the target paediatric population (0-16 years of age) following final confirmation on the trial design from the US Food and Drug Administration (FDA).


At 9:46am: [LON:DNL] Diurnal Group Plc share price was +0.5p at 129.5p



Story provided by StockMarketWire.com